Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis

  • Jaime L Natoli1Email author,
  • Rob Boer1,
  • Brian H Nathanson2,
  • Ross M Miller1,
  • Silvia Chiroli3,
  • William G Goodman4 and
  • Vasily Belozeroff4
BMC Nephrology201314:88

DOI: 10.1186/1471-2369-14-88

Received: 5 December 2012

Accepted: 25 March 2013

Published: 17 April 2013

Abstract

Background

Biochemical markers of altered mineral metabolism have been associated with increased mortality in end stage renal disease patients. Several studies have demonstrated non-linear (U-shaped or J-shaped) associations between these minerals and mortality, though many researchers have assumed linear relationships in their statistical modeling. This analysis synthesizes the non-linear relationships across studies.

Methods

We updated a prior systematic review through 2010. Studies included adults receiving dialysis and reported categorical data for calcium, phosphorus, and/or parathyroid hormone (PTH) together with all-cause mortality. We performed 2 separate meta-analyses to compare higher-than-referent levels vs referent and lower-than-referent levels vs referent levels.

Results

A literature review showed that when a linear relationship between the minerals and mortality was assumed, the estimated associations were more likely to be smaller or non-significant compared to non-linear models. In the meta-analyses, higher-than-referent levels of phosphorus (4 studies, RR = 1.20, 95% CI = 1.15-1.25), calcium (3 studies, RR = 1.10, 95% CI = 1.05-1.14), and PTH (5 studies, RR = 1.11, 95% CI = 1.07-1.16) were significantly associated with increased mortality. Although no significant associations between relatively low phosphorus or PTH and mortality were observed, a protective effect was observed for lower-than-referent calcium (RR = 0.86, 95% CI = 0.83-0.89).

Conclusions

Higher-than-referent levels of PTH, calcium, and phosphorus in dialysis patients were associated with increased mortality risk in a selection of observational studies suitable for meta-analysis of non-linear relationships. Findings were less consistent for lower-than-referent values. Future analyses should incorporate the non-linear relationships between the minerals and mortality to obtain accurate effect estimates.

Keywords

Calcium Dialysis Meta-analysis Mineral metabolism Mortality Parathyroid hormone

Background

Among patients with end stage renal disease (ESRD), the deterioration of kidney function is often accompanied by secondary hyperparathyroidism (SHPT) involving disturbances in mineral metabolism, including elevated levels of serum phosphorus, decreased calcium, and elevated parathyroid hormone (PTH) [1, 2]. Observational studies suggest that biochemical markers of altered mineral metabolism are associated with poor clinical outcomes among patients with ESRD requiring dialysis, although controversy exists regarding the strength of the evidence and the independent nature of these relationships [316].

In a systematic review published in 2008, Covic et al. [17] identified 22 studies published from 1980–2007 that assessed the association between disturbances in biochemical parameters and all-cause mortality among patients with chronic kidney disease (CKD), including 19 studies of patients on dialysis. The authors noted that the studies were too clinically and methodologically diverse to permit an appropriate meta-analysis. Nevertheless, a qualitative assessment of the studies led them to conclude that elevated values in certain biochemical parameters, specifically the serum levels of PTH, calcium, and phosphorus, as well as very low values of phosphorus, were associated with an increase in mortality risk among patients on dialysis.

In contrast to Covic et al., Palmer et al. [18] concluded from their meta-analysis that calcium and PTH did not have statistically significant associations with mortality, but an association between high serum phosphorus and mortality was observed (relative risk [RR] = 1.18, 95% confidence interval [CI] = 1.12-1.25). The Palmer et al. meta-analysis assumed a linear relationship between the serum levels of the 3 biochemical parameters and all-cause mortality, a limitation that they acknowledged could have biased their results.

How the biochemical parameters are modeled is crucial. If the true relationship between the biochemical parameters and mortality is indeed U-shaped or J-shaped, then imposing linear assumptions on a model (either within an individual study or in a meta-analysis) would not accurately quantify the true association (see Figure 1). Often a continuous risk predictor such as age is modeled “as is” without transformations. By doing so, a linear relationship between the predictor and outcome is assumed. If its risk ratio is significantly above 1, then the model implies that for every additional unit (eg, year), the risk increases by a certain constant amount. However, it is possible that both very high and very low values of a variable could increase the risk. Some studies have demonstrated non-linear associations (eg, U-shaped, J-shaped) between phosphorus, calcium, and PTH and mortality risk whereby both low and high serum levels of these variables are associated with an increased risk of death [10, 1416, 1924]. In addition, there is evidence suggesting mortality risk is influenced by interactions between serum calcium and phosphorus [5, 22, 25].
https://static-content.springer.com/image/art%3A10.1186%2F1471-2369-14-88/MediaObjects/12882_2012_Article_529_Fig1_HTML.jpg
Figure 1

Hypothesized relationship between biochemical parameters and mortality risk.

These findings suggest that more advanced statistical methods are required to adequately quantify the true relationship between these biochemical abnormalities and mortality risk in ESRD patients. Researchers have categorized markers (eg, quintiles, high/normal/low groups) as a way to account for non-linear relationships. A few have more rigorously used spline terms [20, 21, 26] (ie, mathematical functions used to model non-linear relationships) and/or tested for interactions [22, 25] (effect modifiers). Unfortunately, since modeling non-linear relationships in regression models is complex, many studies have failed to do so, and the studies that have examined non-linear relationships between biochemical measures and mortality often have not provided results in a format amenable to a traditional meta-analysis.

Thus, the purpose of this study is two-fold. We will review the literature with a special emphasis on the statistical methods used to model the serum levels of PTH, phosphorus, and calcium with mortality. Next, we will use more statistically rigorous meta-analytic methods to improve the estimates of the relationships between biochemical markers of altered mineral metabolism and mortality among patients on dialysis.

Methods

Data sources and search strategy

We searched PubMed, Embase, and Cochrane for English-language articles published subsequent to Covic et al.’s review (ie, 2008–2010) using a search strategy that included terms related to the population, biochemical parameters, and outcomes of interest (see Additional file 1). We reviewed the studies on all-cause mortality among patients on dialysis that were cited by Covic et al. [17] and Palmer et al. [18]. We also reviewed reference lists of relevant primary research and review articles for additional publications.

Initial inclusion criteria and data abstraction

To be included in this review, studies had to (1) have a patient population comprised of adults receiving hemodialysis or peritoneal dialysis; (2) report data on at least one of the selected biochemical parameters, namely calcium, phosphorus, and PTH; and (3) report findings for all-cause mortality. We excluded studies of patients not on dialysis (eg, pre-dialysis CKD, status post-renal transplant) as well as studies that only reported data on calcium-phosphorus product.

Relevant data from each study were abstracted into an evidence table by one investigator (JLN) and were verified by the study statistician (BHN) prior to use in the meta-analysis. Data elements included study characteristics (eg, study design, analytic approach, duration of follow-up), patient characteristics (eg, dialysis type and vintage, age, gender), biochemical parameters and units, time of measurement of biochemical parameters (eg, baseline, time-averaged), and mortality/survivor data.

Literature assessment

For each manuscript that presented a correlation of all-cause mortality data with the biochemical measures of interest, we noted if the authors modeled the biochemical parameters as linear (ie, continuous) predictors of mortality or if they allowed a non-linear relationship with mortality (eg, modeled with splines, modeled as a categorical or binary variable). We also noted if figures were plotted showing the relationship between the parameters and mortality.

Primary meta-analysis approach

To better approximate possible non-linear relationships between biochemical parameters and mortality, we assumed a piecewise linear relationship between each parameter and mortality, and we used each publication’s study-defined referent category. We then performed 2 separate meta-analyses to compare (1) values higher than the referent category vs referent, and (2) values lower than the referent category vs referent.

To be included in the quantitative meta-analysis, each study had to report data on PTH, calcium, and/or phosphorus as categorical variables with the following requirements: (1) the ranges of each category must be specified, (2) the referent category in the study’s multivariate analysis must be the “middle” (ie, both higher-than-referent and lower-than-referent categories were available for comparison), (3) the sample size of each category must be given, and (4) the number of deaths of patients in the multivariate analysis must be given. We also excluded studies with inadequate multivariate analysis (eg, only crude unadjusted results provided, only 1–2 covariates). When RRs were presented graphically without explicit quantitative details, we used a “pencil and ruler” method to extrapolate these values. We did not attempt to contact study authors to inquire about missing data or exact values of graphical data elements.

We also attempted to capture the following statistics for each study: (1) number of deaths per category, (2) person-years per category, (3) covariates in multivariate models, and (4) overall mean and SD of the biochemical parameter and the mean and SD at each categorical level. Unfortunately, both the number of deaths and person-years per biochemical parameter category were not reported in the studies that met our inclusion criteria, and the other statistics were often missing as well.

For the quantitative analysis, we employed the meta-analytic method proposed by Greenland and Longnecker [27] to handle results presented as categorically (with a referent level) and subsequently adapted and expanded upon by Hamling et al. [28]. The Hamling method allows for alternative comparisons of categorical data and is useful when the threshold values in each category are not uniform across studies. For example, studies of cigarette smoking exposure and cancer may present results based on number of pack-years of exposure, and those categories vary across studies. By applying Hamling’s method, one can group dissimilar categories to permit more consistent comparisons across disparate studies (eg, a meta-analysis of any smoking exposure vs. no smoking exposure). In our context, these were relatively high (or low) biochemical parameter values compared to referent.

We used the method of Hamling et al. [28] to derive 2 adjusted RR estimates for each study, one for high values versus the reference range and another for low values versus the reference range. These results were derived from the hazard ratios (HRs) given at the various categorical levels in each study after a multivariate Cox-regression was performed. We assumed a piecewise linear relationship between mortality and the biochemical parameter levels (categories) and that a correlated (non-zero) covariance exists among the series of log RRs. As such, we estimated a variance-covariance matrix of the beta coefficients using the meta-analytic method proposed by Greenland and Longnecker [27]. We also created a meta-regression with the dose estimate at the study level and the time to follow up at the study level as the independent covariate.

All meta-analyses were done with Stata 11.1, StataCorp LP, College Station, TX. Results from the Hamling method were derived from an Excel macro available at http://www.pnlee.co.uk/software.htm[28].

Sensitivity analyses

Since the Hamling method requires an estimate of the number of deaths in the referent category and this was unknown, we conducted a sensitivity analysis by varying our initial mortality estimates in 2 ways: (1) 10% and 15% higher number of deaths, and (2) 10% and 15% lower number of deaths. These cutoffs were selected based on an educated assessment of our uncertainty regarding the number of deaths in the referent category. We then regenerated the meta-analysis results and examined how these variations affected the RRs.

Simulation modeling

As an exploratory analysis, we simulated patient-level results from 5 observational studies selected for large sample size (Block et al. [10], Floege et al. [16], Kalantar-Zadeh et al. [14], Slinin et al. [5], and Tentori et al. [15]). Data for the 3 biochemical parameters were simulated for each of 100,000 hypothetical patients using a lognormal distribution calibrated from the published data of the 5 studies (eg, frequency distribution, mean, standard deviation, correlations between parameters) in order to optimally account for differences in categorization of the biochemical parameters by the respective observational studies. A non-linear dose-effect function (with functional form based on Floege et al. [16]) was applied to the simulated data and calibrated from the observed results. Simulation models were performed using Python 2.6.6 with NumPy 1.5.1rc2 and SciPy 0.8.0.

Results

Overview of studies

The interim search strategy identified 1,548 publications. We ultimately identified 51 studies among patients on dialysis that presented all-cause mortality data correlated with the biochemical measures of interest (see Figure 2 and Table 1).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2369-14-88/MediaObjects/12882_2012_Article_529_Fig2_HTML.jpg
Figure 2

Flow diagram: publications documenting the association between relatively high/low biochemical parameters and mortality.

Table 1

Overview of accepted publications

Author, year

Study or database name

Study design

Duration of follow-up

Dialysis vintage

Dialysis type

Sample size

Allowed for non-linear relationship?*

Was the biochemical parameter associated with mortality after multivariate adjustment?

Graphical depiction?

PTH

Phosphorus

Calcium

Studies with adequate data for meta-analysis

Block 2004 [10]

Fresenius Medical Care

Retrospective cohort

12-18 months (total)

Maintenance

HD

40,538

Yes

Yes

Yes

Yes

Yes (U-shaped for calcium, linear for albumin-adjusted calcium)

Dukkipati 2010 [29]

DaVita-NIED

Prospective cohort

63 months (total)

Maintenance

HD

748

Yes (for PTH only)

Yes

Not stated

Not stated

No

Floege 2011 [16]

European Fresenius Medical Care

Retrospective cohort

20.9 months (median)

Incident or Maintenance

HD

7,970

Yes (also used fractional polynomials)

Yes

Yes

Yes

Yes

Kalantar-Zadeh 2006 [14]

DaVita

Prospective cohort

24 months (total)

Maintenance

HD

58,058

Yes

Yes

Yes

Yes

Yes

Rodriguez-Benot 2005 [24]

Cordoba, Spain

Prospective cohort

97.6 months (median)

Maintenance

HD

385

Yes (for phosphorus and PTH only)

No

Yes

Yes

No

Tangri 2011 [30]

UKRR

Prospective cohort

24 months (total)

Incident

HD, PD

7,076

Yes

Yes

Yes

Yes

No

Tentori 2008 [15]

Dialysis Clinic Inc.

Prospective cohort

16.4 months (median)

Maintenance

HD

25,588

Yes

Yes

Yes

Yes

Yes

Studies that did not qualify for meta-analysis

Block 1998 [31]

USRDS (CMAS and DMMS-1)

Retrospective cohort

2 years

Maintenance

HD

6,407

Yes (also analyzed as continuous linear predictor)

No

Yes

Yes (text and figure are inconsistent)

Yes (J-shaped for phosphorus, linear for calcium and PTH)

Block 2010 [32]

DaVita, CMS-ESRD

Prospective cohort

2.2 years

Maintenance

HD

25,150

Yes

Yes

Yes

Yes

No

Chang 2006 [33]

VA Cooperative Study #440

Post-hoc RCT

4 years

Incident or Maintenance

HD

197

Yes

No

Not measured

Not measured

No

Dreschler 2011 [34]

NECOSAD

Prospective cohort

6 years

Incident

HD, PD

1,628

Yes (for PTH only)

Yes

Not stated

Not stated

No

Dreschler 2011 [35]

NECOSAD

Prospective cohort

3 years

Incident

HD, PD

762

No

Not stated

Not stated

Not stated

No

Etter 2010[36]

monitor!

Prospective cohort

562 days (median)

Maintenance

HD

170

No

No

Not measured

Not measured

No

Foley 1996 [37]

Royal Victoria Hospital

Prospective cohort

5 years

Incident

HD, PD

433

Yes (calcium and phosphorus were binary)

Not measured

No

Yes

No

Ganesh 2001 [7]

USRDS (CMAS and DMMS 1/3/4)

Retrospective cohort

2 years

Maintenance

HD

12,833

Yes

Yes

Yes

Not stated

Yes (U-shaped for PTH)

Gutierrez 2008 [38]

ArMORR (Fresenius)

Prospective cohort

1 year

Incident

HD

10,044

Yes (for phosphorus only)

Not stated

Yes

Not stated

No

Hakemi 2010 [39]

Tehran, Iran

Prospective cohort

18.4 months (mean)

Maintenance

PD

282

Yes (for calcium and PTH only, binary)

Yes

Not measured

Yes

No

Hsiao 2011 [40]

Chang Gung Memorial Hospital

Prospective cohort

1 year

Maintenance

HD

109

No

No

No

Yes

No

Isakova 2009 [41]

ArMORR (Fresenius)

Prospective cohort

1 year

Incident

HD

10,044

Yes (for phosphorus only)

Not stated

Yes

Not stated

No

Jassal 1996 [42]

Belfast City Hospital

Prospective cohort

1 year

Incident

NR

99

No

Not measured

Yes (but not on older subset of patients)

Not measured

No

Jean 2009 [43]

Tassin la Demi-lune, France

Prospective cohort

2 years

Maintenance

HD

219

Yes (for phosphorus only, Not stated for PTH and calcium)

Not stated

No

Not stated

No

Kalantar-Zadeh 2010 [44]

DaVita-Los Angeles

Prospective cohort

5 years

Incident or Maintenance

HD

139,328

Yes

Yes

Yes

Yes

Yes (except for PTH)

Kimata 2007 [45]

DOPPS 1/2 (Japan)

Retrospective cohort

8,056 patient-years

Maintenance

HD

3,973

Yes (also analyzed as continuous linear predictors)

Yes, when linear No, when categorical

Yes, when categorical No, when linear

Yes, for both categorical and linear

Yes for phosphorus No for calcium or PTH

Komaba 2008 [46]

Takasago, Japan

Retrospective cohort

45 months

Maintenance

HD

99

Yes (binary only)

No

Yes (but analyzed with calcium only)

Yes (but analyzed with phosphorus only)

No

Lacson 2009 [47]

Fresenius Knowledge Center

Retrospective cohort

1 year

Maintenance

HD

78,420

In some models

Yes

Yes

Yes

Yes

Leggat 1998 [48]

USRDS (CMAS and DMMS)

Retrospective cohort

2 years

Maintenance

HD

6,251

Yes

Not measured

Yes

Not measured

No

Lin 2010 [49]

Chang Gung Memorial Hospital

Prospective cohort

18 months

Maintenance

PD

315

No

No

No

No

No

Lowrie 1990 [50]

National Medical Care

Cross-sectional

18 months

Maintenance

HD

19,746

No

Not measured

Yes

No

No

Lukowski 2010 [51]

DaVita

Retrospective cohort

3 years

Maintenance

HD

58,917

Yes (for phosphorus only, Not stated for PTH and calcium)

Not stated

Yes

Not stated

Yes for phosphorus No for calcium or PTH

Maeda 2009 [52]

Kyushu University Hospital

Prospective cohort

5 years

Maintenance

HD

226

No

No

No

No

No

McNeill 2010 [53]

DaVita

Cohort, unspecified

3 years

Maintenance

HD

58,917

Yes (for PTH only, Not stated for phosphorus and calcium)

Yes

Not stated

Not stated

Yes for PTH No for calcium or phosphorus

Melamed 2006 [54]

CHOICE

Prospective cohort

2.5 years (median)

Incident

HD, PD

1,007

Yes

Yes (as a time-dependent predictor)

Yes (as a time-dependent predictor)

Yes (as a time-dependent predictor)

No

Miller 2010 [22]

DaVita-Los Angeles

Retrospective cohort

5 years

Maintenance

HD

107,200

Yes

Yes

Yes

Yes

Yes for calcium No for phosphorus or PTH

Miller 2009 [55]

DaVita

Cohort, unspecified

5 years

Maintenance

HD

151,555

Yes

Yes

Yes

Yes

No

Morrone 2009 [56]

MMTE (Italy)

Prospective cohort

18.8 months (mean)

Incident

HD

411

Yes

Yes

Not stated

Not stated

Yes for PTH No for phosphorus or calcium

Naves-Diaz 2011 [57]

Fresenius-CORES

Retrospective cohort

4.5 years

Incident or Maintenance

HD

16,173

Yes

Yes

Yes

Yes

Yes

Naves-Diaz 2008 [58]

Fresenius-CORES

Retrospective cohort

4.5 years

Incident or Maintenance

HD

16,004

Yes

Yes

Yes

Yes

No

Noordzij 2008 [26]

NECOSAD

Prospective cohort

7.8 years

Incident

HD, PD

1,621

Yes (restricted cubic splines)

Not stated

Yes

Yes

Yes (spline)

Noordzij 2005 [23]

NECOSAD

Prospective cohort

7.5 years (max)

Incident

HD, PD

1,629

Yes

No

Yes

No

No

Phelan 2008 [59]

Beaumon Hospital (Ireland)

Retrospective cohort

4.5 years (mean)

Incident

HD, PD

1,007

Yes (binary only)

No

Yes

No

No

Port 2004 [60]

DOPPS I

Prospective cohort

5 years

Maintenance

HD

17,245

Yes (for phosphorus only, binary)

Not measured

Yes

Not measured

No

Saran 2003 [61]

DOPPS

Retrospective cohort

1.8-2.9 years (median, depending on region)

Maintenance

HD

14,930

Yes (for phosphorus only, binary)

No

Yes

Not measured

No

Shinaberger 2008 [20]

DaVita

Retrospective cohort

3 years

Maintenance

HD

30,075

Yes (restricted cubic splines)

Not stated

Yes

Not stated

Yes

Shinaberger 2008 [21]

DaVita

Retrospective cohort

3 years

Maintenance

HD

34,307

Yes (restricted cubic splines, PTH only)

Yes

Not stated

Not stated

Yes

Simic-Ogrizovic 2009 [62]

Clinical Center of Serbia

Prospective cohort

3 years

Maintenance

HD

130

No

Not measured

Yes

No

No

Sit 2008 [63]

Dicle University

Retrospective cohort

10 years

Maintenance

NR

1,538

No

Yes

No

No

No

Slinin 2005 [5]

USRDS (1/2/3)

Retrospective cohort

3.9 years (mean)

Maintenance

HD

14,829

Yes

Yes

Yes

Yes

No

Stevens 2004 [25]

PROMIS

Prospective cohort

2.6 years (median)

Maintenance

HD, PD

515

Yes (examined interactions; also modeled continuous, linear predictors)

No, when continuous Yes, when categorical with interactions

Yes, for both continuous and categorical with interactions

No, when continuous Yes, when categorical with interactions

No

Takemoto 2009 [64]

Toranomon Hospital

Prospective cohort

8 years

Maintenance

HD

68

No

Yes

No

No

No

Wald 2008 [65]

HEMO

Post-hoc RCT

6.5 years

Maintenance

HD

1,846

Yes

No

Yes

Yes

Yes for calcium and phosphorus No for PTH

Young 2004 [66]

DOPPS 1/2

Retrospective cohort

2 years

Maintenance

HD

15,475

No

Yes

Yes

Yes

No

HD, hemodialysis; NR, not reported; PD, peritoneal dialysis; PTH, parathyroid hormone; RCT, randomized controlled trial.

* Study explicitly allowed for a non-linear relationship between biochemical parameters and mortality (eg, use of a categorical variable or splines).

†Study provided a graphical depiction of the relationship between biochemical parameters and mortality.

As noted in Table 1, most studies found a significant relationship between the 3 biochemical measures and mortality. Twelve studies (23.5%) modeled the biochemical measures as linear, continuous variables. Furthermore, no paper included explicit discussion of testing for non-linearity to justify this decision. Another 14 studies (27.5%) attempted to model these variables in a non-linear manner but only did so for some measures (eg, just phosphorus) or merely dichotomized the variable rather than use multiple categories or splines. Only 5 of 51 studies used spline functions even though this is the most rigorous method to handle non-linearity and prevents a loss of power compared to categorization [67].

The choice of a linear or non-linear model also affected results. In 8 studies that measured PTH and modeled it linearly, 4 (50.0%) found no significant association with mortality. In contrast, in the 37 studies that modeled PTH with categories or splines, just 8 (21.6%) found no significant association. For phosphorus, 5 of 11 studies with linear models (45.5%) found no association with mortality compared to 2 of 37 studies (5.4%) in which phosphorus was modeled as a non-linear predictor. Similarly for calcium, 4 of 10 studies with linear models (40.0%) explicitly stated no association with mortality compared to 2 of 37 non-linear studies (5.4%). Nineteen of 51 studies graphed at least one categorized predictor (eg, by quartile) by either percent dying or by adjusted RR. In 18 of 19 studies (94.7%), a non-linear U or J shape was evident for at least one of these variables.

Primary meta-analysis findings

Seven studies were included in the meta-analysis (see Table 2) because the majority of candidate reports did not contain the necessary data elements. Of the 7 studies, 4 included relevant data on phosphorus [10, 14, 24, 30], 3 on calcium [10, 14, 30], and 5 on PTH [1416, 29, 30]. Although we made no restrictions based on study design or dialysis type, all of the included studies were prospective or retrospective cohort studies, and virtually all patients received hemodialysis.
Table 2

Summary of studies included in meta-analysis

Author, year

Study or database name

Study design

Duration of follow-up

Dialysis vintage

Dialysis type

Sample size

Biochemical parameters with adequate data

Timing of assessment

Model adjustment

Block, 2004 [10]

Fresenius Medical Care

Retrospective cohort

12-18 months (total)

Maintenance

HD

40,538

P, Ca

Average of values in first 3 months of study

Multivariate adjusted

Dukkipati, 2010 [29]

DaVita-NIED

Prospective cohort

63 months (total)

Maintenance

HD

748

PTH

Baseline, drawn prior to dialysis session

Multivariate (MICS) adjusted

Floege, 2011 [16]

European Fresenius Medical Care

Retrospective cohort

20.9 months (median)

Incident, 35% Maintenance, 65%

HD

7,970

PTH

Average of values in 1st quarter of follow-up

Multivariate, time-dependent adjusted

Kalantar-Zadeh, 2006 [14]

DaVita

Prospective cohort

24 months (total)

Maintenance

HD

58,058

P, Ca, PTH

Average of values in 1st quarter of follow-up

Multivariate (MICS), time-dependent adjusted

Rodriguez-Benot, 2005 [24]

Cordoba, Spain

Prospective cohort

97.6 months (median)

Maintenance

HD

385

P

6-month mean prior to death or end of study period

Multivariate adjusted

Tangri, 2011 [30]

UKRR

Prospective cohort

24 months (total)

Incident

HD, 70% PD, 30%

7,076

P, Ca, PTH

Average of values during the first year of dialysis

Multivariate adjusted

Tentori, 2008 [15]

Dialysis Clinic Inc.

Prospective cohort

16.4 months (median)

Maintenance

HD

25,588

PTH*

Baseline

Multivariate adjusted

Ca, calcium; HD, hemodialysis; MICS, malnutrition-inflammation complex syndrome; NIED, Nutritional and Inflammatory Evaluation in Dialysis; P, phosphorus; PD, peritoneal dialysis; PTH, parathyroid hormone; UKRR, United Kingdom Renal Registry.

*Excluded data for the other biochemical parameters due to discrepancies between sample sizes presented in publication tables and manuscript text.

Reference ranges were generally consistent across studies. The midpoints of the reference ranges were ≈4-4.5 mg/dL for phosphorus (with the exception of Kalantar-Zadeh 2006 [14], which was 5.5 mg/dL), ≈9-9.25 mg/dL for calcium, and ≈225-250 pg/mL for PTH (with the exception of Dukkipati 2010 [29], which was 450 pg/mL). Figures 3a-c provide graphical depictions of the HRs from the studies used in each meta-analysis.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2369-14-88/MediaObjects/12882_2012_Article_529_Fig3_HTML.jpg
Figure 3

Studies used in the meta-analysis of biochemical parameters and mortality. In these studies, biochemical parameter levels were analyzed as categorical variables. In order to visualize the relationship between mortality and the biochemical parameters, the values on the x-axis for each symbol in the figure represent the midpoint within each category for each study. In order to make the graphical representation more comparable across studies, we adjusted the HRs so that the midpoint of the reference range was as similar as possible. We stress that this is done just for the figures only and not for the meta-analyses. Specific adjustments are noted below. a. Phosphorus: The midpoints of reference ranges were ≈4- 4.5 mg/dL across all studies with the exception of Kalantar-Zadeh 2006 [14]. For this study, we adjusted the graphical depiction of the reference range from 5–6 mg/dL to 4–5 mg/dL. Of note, non-linear relationships were most clearly evident in the 2 studies with the largest sample sizes. b. Calcium: The midpoints of reference ranges were ≈9-9.25 mg/dL across all studies. No studies had to be adjusted for graphical display. c. PTH: The midpoints of reference ranges were ≈225-250 pg/mL across all studies with the exception of Dukkipati 2010 [29]. For this study, we adjusted the graphical depiction of the reference range from 300–600 pg/mL to 200–249 pg/mL.

We present the adjusted RRs based on the Hamling method for each study in Table 3 (relatively high values versus referent) and Table 4 (relatively low versus referent). Table 5 summarizes the derived RRs from each meta-analysis. Higher-than-referent levels of phosphorus (RR = 1.20, 95% CI=1.15-1.25), calcium (RR = 1.10, 95% CI=1.05-1.14), and PTH (RR = 1.11, 95% CI=1.07-1.16) were all significantly associated with an increased risk of mortality. Although no significant associations between relatively low phosphorus or PTH and mortality were observed, there did appear to be a protective effect for relatively low calcium and mortality (RR = 0.86, 95% CI = 0.83-0.89).
Table 3

Mortality risk for relatively high biochemical parameter values versus referent values

Study

Reference range

N*

RR for high values vs. referent (95% CI)

Follow-up (months)

Phosphorus (mg/dL)

Block 2004 [10]

4.0-5.0

35,783

1.21 (1.14-1.29)

18

Kalantar-Zadeh 2006 [14]

5.0-6.0

36,955

1.20 (1.13-1.29)

24

Rodriguez-Benot 2005 [24]

3.0-5.0

375

1.96 (1.20-3.18)

97.6

Tangri 2010 [30]

3.5-5.5

6,538

0.74 (0.53-1.03)

24

Calcium (mg/dL)

Block 2004 [10]

9.0-9.5

23,168

1.14 (1.06-1.22)

30

Kalantar-Zadeh 2006 [14]

9.0-9.5

36,831

1.06 (1.00-1.12)

24

Tangri 2010 [30]

8.4-9.5

6,843

1.23 (0.95-1.58)

24

Parathyroid hormone (pg/mL)

Dukkipati 2010 [29]

300-600

288

0.96 (0.60-1.55)

63

Floege 2010 [16]

150-300

2,443

1.35 (1.14-1.61)

20.9

Kalantar-Zadeh 2006 [14]

200-300

29,273

1.12 (1.06-1.18)

24

Tangri 2010 [30]

151-300

4,842

0.92 (0.71-1.20)

24

Tentori 2008 [15]

100-300

18,224

1.09 (1.02-1.16)

18.7

CI, confidence interval; RR, risk ratio.

*Sample size includes patients in the reference range plus those with relatively high biochemical parameter values.

†The median or mean (or total, if median was not given) follow-up time in each study.

Table 4

Mortality risk for relatively low biochemical parameter values versus referent values

Study

Reference range

N*

RR for low values vs. referent (95% CI)

Follow-up (months)

Phosphorus (mg/dL)

Block 2004 [10]

4.0-5.0

13,478

1.01 (0.95-1.08)

18

Kalantar-Zadeh 2006 [14]

5.0-6.0

34,636

0.99 (0.88-1.12)

24

Rodriguez-Benot 2005 [24]

3.0-5.0

170

0.41 (0.05-3.26)

97.6

Tangri 2011 [30]

3.5-5.5

4,776

1.22 (1.01-1.49)

24

Calcium (mg/dL)

Block 2004 [10]

9.0-9.5

28,129

0.81 (0.77-0.85)

30

Kalantar-Zadeh 2006 [14]

9.0-9.5

37,662

0.93 (0.87-0.98)

24

Tangri 2011 [30]

8.4-9.5

3,394

1.35 (0.24-7.48)

24

Parathyroid hormone (pg/mL)

Dukkipati 2010 [29]

300-600

648

0.72 (0.52-0.95)

63

Floege 2010 [16]

150-300

2,595

1.31 (1.14-1.51)

20.9

Kalantar-Zadeh 2006 [14]

200-300

33,758

0.99 (0.94-1.05)

24

Tangri 2011 [30]

151-300

5,071

0.84 (0.61-1.16)

24

Tentori 2008 [15]

100-300

17,648

1.00 (0.93-1.08)

18.7

CI, confidence interval; RR, risk ratio.

*Sample size includes patients in the reference range plus those with relatively low biochemical parameter values.

†The median or mean (or total, if median was not given) follow-up time in each study.

Table 5

Summary of findings: meta-analyses of mortality risk for relatively high/low biochemical parameter values versus referent values*

Biochemical parameter

Mortality risk for relatively low biochemical parameter values

Mortality risk for relatively high biochemical parameter values

Risk ratio (95% CI)

I2

Risk ratio (95% CI)

I2

Phosphorus

1.02 (0.97-1.08)

30.5%

1.20 (1.15-1.25)

75.2%

Calcium

0.86 (0.83-0.89)

84.0%

1.10 (1.05-1.14)

39.9%

PTH

1.01 (0.97-1.05)

79.8%

1.11 (1.07-1.16)

47.8%

*Statistical heterogeneity: the I2 statistic describes the percent of variation in the risk ratio that is attributable to heterogeneity in a meta-analysis.

We conducted 6 meta-regressions to examine the effect of follow-up time on the RR estimates, one for each biochemical parameter at relatively low and high values. Results from the meta-regression indicated that follow-up time did not have a statistically significant effect on the RRs (data not shown).

Sensitivity analysis

We varied the baseline estimated number of deaths and non-deaths in the referent group when doing the Hamling analysis by 10% to 15% in both directions. Results of these sensitivity analyses demonstrated that the estimated RR values were extremely stable and almost identical to the original estimates (data not shown). Due to the dissimilar reference range used by Dukkipati, we also re-ran the original meta-analyses without this study. The overall effect estimates and measures of heterogeneity were not appreciably different from those in the primary analysis (data not shown).

Simulation analysis

Preliminary work on a simulation of 5 large observational studies (Block et al. [10], Floege et al. [16], Kalantar-Zadeh et al. [14], Slinin et al. [5], and Tentori et al. [15]), in which we estimated continuous functions for the relationship between mortality and each of the 3 biochemical parameters also showed non-linear U- or J-shaped trends that were a good fit with the published data. Similar to the meta-analysis, the simulation showed significant heterogeneity among the studies for all 3 biochemical parameters. The source of the heterogeneity was not obvious.

Discussion

Our literature review shows that most studies found a significant relationship between serum levels of PTH, calcium, and phosphorus and mortality even though a sizeable number naively modeled these variables as linear predictors. Another large group of studies only examined these variables as binary variables, which is a methodologically weak approach. For example, Phelan et al. [59] found no relationship between PTH above and below 300 pg/ml and mortality. Interestingly, they correctly deduced that this result may be because very high PTH values could have “cancelled out” very low PTH values and both extremes may be harmful. However, they did not take corrective actions (eg, more categories, spline functions) in their methods. We also rarely encountered a paper that reported explicit power calculations, which is important given that categorizing a variable reduces power. Thus, it is important to acknowledge that the statistical methods used in the literature may be insufficient and the results should be cautiously interpreted.

In our meta-analysis, higher-than-referent (often “normal”) serum levels of PTH, calcium, and phosphorus in dialysis patients were positively associated with increased mortality. For lower-than-referent values, findings were less consistent across the 3 selected parameters; we observed no significant association for phosphorus and PTH and reduced mortality for relatively low values of calcium. The correlation between increased mortality and elevated biochemical parameter values was expected based on the assumption that levels within a “normal” range represent optimal health. The lack of statistical significance for lower values of phosphorus and PTH may be partly attributable to the small numbers of dialysis patients with sub-referent levels, leading to low statistical power. Although low serum calcium is not typically considered “healthy,” the association with significantly lower mortality risk is not completely surprising and may be explained by lower vascular calcification and associated mortality [10, 6872].

Although our findings for phosphorus and mortality are in line with those of the recent meta-analysis by Palmer et al. [18], our findings for calcium and PTH differ as Palmer et al. did not demonstrate a significant mortality risk for either calcium or PTH. There are several reasons for this disparity. First, the Palmer study assumed a linear relationship between the biochemical parameters and mortality over the total range of values, while our study used a piecewise linear approach that allowed for the possibility of U-shaped or J-shaped relationships. As Figure 1 illustrates, if the relationship is U-shaped or J-shaped, a linear assumption may incorrectly estimate the magnitude of the association. In fact, when studies did model a biochemical parameter as both a continuous, linear predictor and then as a categorical variable, the RRs were more extreme with the categorical approach [45, 47]. The Palmer study also included studies of patients who were not on dialysis, such as patients with pre-dialysis CKD and ESRD patients who had received kidney transplants. If the relationship between abnormal biochemical parameters and mortality is strongest among the sickest patients (ie, those on dialysis), this would further attenuate the estimated relationship. Furthermore, some studies that were included in Palmer’s meta-analysis could not be utilized with our meta-analytic approach as our requirements for analysis were more stringent.

Using very similar review methods to ours, Covic et al. [17] concluded that quantitative synthesis in a meta-analysis was not possible due to significant clinical and methodological heterogeneity across the identified studies. Although we attempted to resolve this by including additional, more recent studies and by focusing on a more clinically narrow population of ESRD patients, we still observed clinical and methodological heterogeneity in the included studies. Aside from the types of differences documented by Covic et al. [17], including variations for dialysis vintage and covariates included in the respective multivariate models, we theorize that the clinical context of these studies may be an important source of heterogeneity. For example, management of biochemical abnormalities and/or other aspects of patient care may vary across institutions or according to geographic region (eg, vitamin D use). It is worth noting that most studies found a significant association with all 3 variables and mortality and when the variables were graphed against mortality, frequently a U or J shape was observed.

Our meta-analysis has specific limitations. Although we did not perform independent, dual data abstraction (the gold standard for systematic reviews), we employed a rigorous quality review of abstracted data, and we do not believe that this approach compromised the accuracy of our results. Additionally, while several statistically significant associations between biochemical parameters and mortality were found, we stress that association alone does not necessitate a causal relationship. For example, relatively high values of any of the 3 biochemical parameters may reflect the general health of a patient, which may not change as a result of treatment geared to normalizing a single abnormality. Furthermore, many patients in these observational studies received medications aimed at correcting (or preventing) out-of-range levels; their ability to respond to such therapies may have reflected their general health.

In addition, we excluded several large studies because their results could not be synthesized in our meta-analysis due to the way the results were reported. All meta-analyses are limited by the availability of pertinent data in relevant publications, and the study by Palmer et al. also excluded many studies for a variety of reasons. Nevertheless, our analysis of abnormally low values may have been underpowered and we encourage future studies to look at this clinically uncommon subset of patients in more detail.

Our study analyzed the association between biochemical parameter values above and below the referent value of a study in order to better approximate non-linearity, although this approach still assumes linear relationships above and below the reference range. However, not all studies used a reference range that would be expected to include the nadir of the curve, which leads to a lower-than-expected slope estimate for the segment of the curve that includes the nadir of the U-shape or J-shape. This underestimation is similar to that due to assuming a linear effect, although the magnitude of bias is much smaller. The 2 studies [14, 29] that chose a reference range outside of “normal” bounds both used values that were higher than the other studies with which they were meta-analyzed; this may have led to an underestimation of the effect of relatively low values.

Finally, the historical approach to altered mineral metabolism has been somewhat reductionist as studies tend to evaluate individual biochemical parameters in isolation and assume independence across those parameters. Unfortunately, a more comprehensive approach that explores the interactions between biochemical parameters for mortality effects has not been well researched [25]. While some studies reported data on calcium-phosphorus product, not all investigated the extent to which their results showed interaction between calcium and phosphorus, and the main effects of calcium and phosphorus were not always reported, which is a major methodological shortcoming. Therefore, our meta-analysis did not consider interactions. The lack of investigation of interactions further hinders direct applicability of the results of observational studies to determine the quantitative targets of practice guidelines.

Conclusions

In summary, we conclude that the relationships between phosphorus, calcium, and PTH and mortality among ESRD patients receiving dialysis appear to not be linear but rather trend towards non-linear U-shaped or J-shaped curves. In addition, we found that elevated values of all 3 of these biochemical parameters were associated with increased mortality. Also, our literature review shows that many studies have naively modeled the relationship between these biochemical markers and mortality making their interpretation problematic at best. Prior meta-analyses of studies that have not correctly modeled these biochemical markers cannot be considered definitive. Instead, we suggest that future studies use more advanced modeling techniques (eg, spline terms, interactions) on large datasets in order to better describe possible non-linear relationships between the biochemical markers and mortality.

Author’s contributions

JN was responsible for the design and conduct of the systematic review, design of meta-analysis, interpretation of results, and composition of all sections of the manuscript. RB was responsible for the design of the meta-analysis, interpretation of results, composition of the Discussion section, and review of the manuscript. BN was responsible for the design and conduct of the meta-analysis, interpretation of results, and composition of all sections of the manuscript. RM was responsible for the design of the systematic review, interpretation of results, and review of the manuscript. SC, WG, and VB are all employees and stockholders in Amgen Inc and each contributed to the interpretation of results, writing and review of the manuscript. All authors read and approved the final manuscript.

Declarations

Acknowledgements

We wish to thank Geoffrey A. Block, MD, for his valuable input on early drafts of this manuscript and Holly Tomlin, MPH (employee and stockholder, Amgen Inc.) and Lisa Kaspin, PhD (employee and stockholder, Cerner Research) for editing and journal formatting assistance.

Authors’ Affiliations

(1)
Cerner Research
(2)
OptiStatim, LLC
(3)
Amgen Europe
(4)
Amgen

References

  1. Owda A, Elhwairis H, Narra S, Towery H, Osama S: Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003, 25: 595-602. 10.1081/JDI-120022551.View ArticlePubMedGoogle Scholar
  2. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999, 73: S14-S19.View ArticlePubMedGoogle Scholar
  3. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998, 32: S112-S119. 10.1053/ajkd.1998.v32.pm9820470.View ArticlePubMedGoogle Scholar
  4. Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol. 1998, 11: 239-245.PubMedGoogle Scholar
  5. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005, 16: 1788-1793. 10.1681/ASN.2004040275.View ArticlePubMedGoogle Scholar
  6. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, Heimburger O, Lindholm B, Bergstrom J: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000, 57: 1727-1735. 10.1046/j.1523-1755.2000.00018.x.View ArticlePubMedGoogle Scholar
  7. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001, 12: 2131-2138.PubMedGoogle Scholar
  8. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E: Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl. 2003, 85: S111-S114.View ArticlePubMedGoogle Scholar
  9. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005, 67: 1179-1187. 10.1111/j.1523-1755.2005.00185.x.View ArticlePubMedGoogle Scholar
  10. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004, 15: 2208-2218. 10.1097/01.ASN.0000133041.27682.A2.View ArticlePubMedGoogle Scholar
  11. de Francisco AL: Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther. 2004, 26: 1976-1993. 10.1016/j.clinthera.2004.12.011.View ArticlePubMedGoogle Scholar
  12. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, Akiba T, Keen ML, Young EW, Port FK: High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008, 74: 655-663. 10.1038/ki.2008.248.View ArticlePubMedGoogle Scholar
  13. Avram MM, Mittman N, Myint MM, Fein P: Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2001, 38: 1351-1357. 10.1053/ajkd.2001.29254.View ArticlePubMedGoogle Scholar
  14. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006, 70: 771-780. 10.1038/sj.ki.5001514.View ArticlePubMedGoogle Scholar
  15. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008, 52: 519-530. 10.1053/j.ajkd.2008.03.020.View ArticlePubMedGoogle Scholar
  16. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011, 26: 1948-1955. 10.1093/ndt/gfq219.View ArticlePubMedGoogle Scholar
  17. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D: Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009, 24: 1506-1523. 10.1093/ndt/gfn613.View ArticlePubMedGoogle Scholar
  18. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011, 305: 1119-1127. 10.1001/jama.2011.308.View ArticlePubMedGoogle Scholar
  19. Cunningham J, Silver J: CKD-MBD: comfort in the trough of the U. Nephrol Dial Transplant. 2011, 26: 1764-1766. 10.1093/ndt/gfr205.View ArticlePubMedGoogle Scholar
  20. Shinaberger CS, Greenland S, Kopple JD, Van WD, Mehrotra R, Kovesdy CP, Kalantar-Zadeh K: Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am J Clin Nutr. 2008, 88: 1511-1518. 10.3945/ajcn.2008.26665.View ArticlePubMedGoogle Scholar
  21. Shinaberger CS, Kopple JD, Kovesdy CP, McAllister CJ, Van WD, Greenland S, Kalantar-Zadeh K: Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008, 3: 1769-1776. 10.2215/CJN.01760408.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Miller JE, Kovesdy CP, Norris KC, Mehrotra R, Nissenson AR, Kopple JD, Kalantar-Zadeh K: Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol. 2010, 32: 403-413. 10.1159/000319861.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT: The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. 2005, 46: 925-932. 10.1053/j.ajkd.2005.08.013.View ArticlePubMedGoogle Scholar
  24. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P: Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005, 46: 68-77. 10.1053/j.ajkd.2005.04.006.View ArticlePubMedGoogle Scholar
  25. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004, 15: 770-779. 10.1097/01.ASN.0000113243.24155.2F.View ArticlePubMedGoogle Scholar
  26. Noordzij M, Korevaar JC, Dekker FW, Boeschoten EW, Bos WJ, Krediet RT, Bossuyt PM, Geskus RB: Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline. Blood Purif. 2008, 26: 231-237. 10.1159/000118847.View ArticlePubMedGoogle Scholar
  27. Greenland S, Longnecker MP: Methods for trend estimation from summarized dose–response data, with applications to meta-analysis. Am J Epidemiol. 1992, 135: 1301-1309.PubMedGoogle Scholar
  28. Hamling J, Lee P, Weitkunat R, Ambuhl M: Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med. 2008, 27: 954-970. 10.1002/sim.3013.View ArticlePubMedGoogle Scholar
  29. Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, Kopple JD, Kalantar-Zadeh K: Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010, 20: 243-254. 10.1053/j.jrn.2009.10.006.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Tangri N, Wagner M, Griffith JL, Miskulin DC, Hodsman A, Ansell D, Naimark DM: Effect of Bone Mineral Guideline Target Achievement on Mortality in Incident Dialysis Patients: An Analysis of the United Kingdom Renal Registry. Am J Kidney Dis. 2011, 57: 415-421. 10.1053/j.ajkd.2010.08.037.View ArticlePubMedGoogle Scholar
  31. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998, 31: 607-617. 10.1053/ajkd.1998.v31.pm9531176.View ArticlePubMedGoogle Scholar
  32. Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL: Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010, 78: 578-589. 10.1038/ki.2010.167.View ArticlePubMedGoogle Scholar
  33. Chang JJ, Concato J, Wells CK, Crowley ST: Prognostic implications of clinical practice guidelines among hemodialysis patients. Hemodial Int. 2006, 10: 399-407. 10.1111/j.1542-4758.2006.00137.x.View ArticlePubMedGoogle Scholar
  34. Drechsler C, Grootendorst DC, Boeschoten EW, Krediet RT, Wanner C, Dekker FW: Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients. Nephrol Dial Transplant. 2011, 26: 1340-1346. 10.1093/ndt/gfq541.View ArticlePubMedGoogle Scholar
  35. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, Wanner C, Boeschoten EW, Brandenburg V: Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2011, 26: 1024-1032. 10.1093/ndt/gfq606.View ArticlePubMedGoogle Scholar
  36. Etter C, Straub Y, Hersberger M, Raz HR, Kistler T, Kiss D, Wuthrich RP, Gloor HJ, Aerne D, Wahl P, Klaghofer R, Ambuhl PM: Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis. Eur Heart J. 2010, 31: 354-359. 10.1093/eurheartj/ehp429.View ArticlePubMedGoogle Scholar
  37. Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol. 1996, 16: 386-393. 10.1159/000169030.View ArticlePubMedGoogle Scholar
  38. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, 359: 584-592. 10.1056/NEJMoa0706130.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Hakemi MS, Golbabaei M, Nassiri A, Kayedi M, Hosseini M, Atabak S, Ganji MR, Amini M, Saddadi F, Najafi I: Predictors of patient survival in continuous ambulatory peritoneal dialysis: 10-year experience in 2 major centers in Tehran. Iran J Kidney Dis. 2010, 4: 44-49.PubMedGoogle Scholar
  40. Hsiao CH, Chao A, Chu SY, Lin KK, Yeung L, Lin-Tan DT, Lin JL: Association of severity of conjunctival and corneal calcification with all-cause 1-year mortality in maintenance haemodialysis patients. Nephrol Dial Transplant. 2011, 26: 1016-1023. 10.1093/ndt/gfq485.View ArticlePubMedGoogle Scholar
  41. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M: Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009, 20: 388-396. 10.1681/ASN.2008060609.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Jassal SV, Douglas JF, Stout RW: Prognostic markers in older patients starting renal replacement therapy. Nephrol Dial Transplant. 1996, 11: 1052-1057. 10.1093/oxfordjournals.ndt.a027455.View ArticlePubMedGoogle Scholar
  43. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009, 24: 2792-2796. 10.1093/ndt/gfp191.View ArticlePubMedGoogle Scholar
  44. Kalantar-Zadeh K, Miller JE, Kovesdy CP, Mehrotra R, Lukowsky LR, Streja E, Ricks J, Jing J, Nissenson AR, Greenland S, Norris KC: Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res. 2010, 25: 2448-2458.View ArticleGoogle Scholar
  45. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi Y, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK: Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. 2007, 11: 340-348. 10.1111/j.1542-4758.2007.00190.x.View ArticlePubMedGoogle Scholar
  46. Komaba H, Igaki N, Takashima M, Goto S, Yokota K, Komada H, Takemoto T, Kohno M, Kadoguchi H, Hirosue Y, Goto T: Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial. 2008, 12: 42-48. 10.1111/j.1744-9987.2007.00539.x.View ArticlePubMedGoogle Scholar
  47. Lacson E, Wang W, Hakim RM, Teng M, Lazarus JM: Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis. 2009, 53: 79-90. 10.1053/j.ajkd.2008.07.031.View ArticlePubMedGoogle Scholar
  48. Leggat JE, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK: Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis. 1998, 32: 139-145. 10.1053/ajkd.1998.v32.pm9669435.View ArticlePubMedGoogle Scholar
  49. Lin JL, Lin-Tan DT, Chen KH, Hsu CW, Yen TH, Huang WH, Huang YL: Blood lead levels association with 18-month all-cause mortality in patients with chronic peritoneal dialysis. Nephrol Dial Transplant. 2010, 25: 1627-1633. 10.1093/ndt/gfp663.View ArticlePubMedGoogle Scholar
  50. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990, 15: 458-482.View ArticlePubMedGoogle Scholar
  51. Lukowsky L, Kovesdy CP, McNeill G, Streja E, Jing J, Krishnan M, Nissenson AR, Kalantar-Zadeh K: Comparing mortality-predictability of hyperphosphatemia in maintenance hemodialysis patients with and without Polycystic Kidney Disease (PKD). Am J Kidney Dis. 2010, 55: A76-View ArticleGoogle Scholar
  52. Maeda S, Sawayama Y, Furusyo N, Shigematsu M, Hayashi J: The association between fatal vascular events and risk factors for carotid atherosclerosis in patients on maintenance hemodialysis: plaque number of dialytic atherosclerosis study. Atherosclerosis. 2009, 204: 549-555. 10.1016/j.atherosclerosis.2008.09.028.View ArticlePubMedGoogle Scholar
  53. McNeill G, Streja E, Lukowsky L, Kovesdy CP, Jing J, Krishnan M, Nissenson AR, Kalantar-Zadeh K: Secondary hyperparathyroidism & survival in hemodialysis patients with & without polycystic kidney. Am J Kidney Dis. 2010, 55: A79-View ArticleGoogle Scholar
  54. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006, 70: 351-357. 10.1038/sj.ki.5001542.View ArticlePubMedGoogle Scholar
  55. Miller JE, Streja E, Kovesdy CP, Wyck DV, Nissenson AR, Kalantar-Zadeh K: Mortality of 5-Year time-averaged low serum calcium <8.5 mg/dL in subgroups of hemodialysis (HD) patients. Am J Kidney Dis. 2009, 53: A55-Google Scholar
  56. Morrone LF, Mazzaferro S, Russo D, Aucella F, Cozzolino M, Facchini MG, Galfre A, Malberti F, Mereu MC, Nordio M, Pertosa G, Santoro D: Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients. Nephrol Dial Transplant. 2009, 24: 2859-2865. 10.1093/ndt/gfp170.View ArticlePubMedGoogle Scholar
  57. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernandez-Martin JL, Rodriguez-Puyol D, Cannata-Andia JB: Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011, 26: 1938-1947. 10.1093/ndt/gfq304.View ArticlePubMedGoogle Scholar
  58. Naves-Diaz M, Varez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andia JB: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008, 74: 1070-1078. 10.1038/ki.2008.343.View ArticlePubMedGoogle Scholar
  59. Phelan PJ, O'Kelly P, Walshe JJ, Conlon PJ: The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail. 2008, 30: 423-429. 10.1080/08860220801964236.View ArticlePubMedGoogle Scholar
  60. Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, Held PJ: DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif. 2004, 22: 175-180. 10.1159/000074938.View ArticlePubMedGoogle Scholar
  61. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kurokawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK: Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 2003, 64: 254-262. 10.1046/j.1523-1755.2003.00064.x.View ArticlePubMedGoogle Scholar
  62. Simic-Ogrizovic S, Dopsaj V, Bogavac-Stanojevic N, Obradovic I, Stosovic M, Radovic M: Serum amyloid-A rather than C-reactive protein is a better predictor of mortality in hemodialysis patients. Tohoku J Exp Med. 2009, 219: 121-127. 10.1620/tjem.219.121.View ArticlePubMedGoogle Scholar
  63. Sit D, Kadiroglu AK, Kayabasi H, Kara IH, Yilmaz Z, Yilmaz ME: The evaluation incidence and risk factors of mortality among patients with end stage renal disease in Southeast Turkey. Ren Fail. 2008, 30: 37-44. 10.1080/08860220701741965.View ArticlePubMedGoogle Scholar
  64. Takemoto F, Katori H, Sawa N, Hoshino J, Suwabe T, Nakanishi S, Arai S, Fukuda S, Kodaka K, Shimada M, Yamazaki C, Yokoyama K, Nakano Y, Funahashi T, Ubara Y, Yamada A, Takaichi K, Uchida S: Plasma adiponectin: a predictor of coronary heart disease in hemodialysis patients–a Japanese prospective eight-year study. Nephron Clin Pract. 2009, 111: c12-c20. 10.1159/000178818.View ArticlePubMedGoogle Scholar
  65. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC: Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis. 2008, 52: 531-540. 10.1053/j.ajkd.2008.05.020.View ArticlePubMedGoogle Scholar
  66. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004, 44: 34-38.View ArticlePubMedGoogle Scholar
  67. Harrell FE: Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. 2001, New York, NY: Springer-VerlagGoogle Scholar
  68. Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Santos RD, Miname M, Canziani ME: The progression and impact of vascular calcification in peritoneal dialysis patients. Perit Dial Int. 2007, 27: 340-346.PubMedGoogle Scholar
  69. Fensterseifer DM, Karohl C, Schvartzman P, Costa CA, Veronese FJ: Coronary calcification and its association with mortality in haemodialysis patients. Nephrology (Carlton). 2009, 14: 164-170. 10.1111/j.1440-1797.2008.01020.x.View ArticleGoogle Scholar
  70. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S: Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004, 8: 54-58. 10.1007/s10157-003-0260-0.View ArticlePubMedGoogle Scholar
  71. Shantouf RS, Budoff MJ, Ahmadi N, Ghaffari A, Flores F, Gopal A, Noori N, Jing J, Kovesdy CP, Kalantar-Zadeh K: Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. Am J Nephrol. 2010, 31: 419-425. 10.1159/000294405.View ArticlePubMedPubMed CentralGoogle Scholar
  72. Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007, 2: 1241-1248. 10.2215/CJN.02190507.View ArticlePubMedGoogle Scholar
  73. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/14/88/prepub

Copyright

© Natoli et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.